Pharmacodynamic effects of haematopoietic cytokines: The view of a clinical oncologist

Basic and Clinical Pharmacology and Toxicology

Volumn 106, Issue 3, 2010, Pages 210-214

  Held, Thomas K ^a   Gundert Remy, Ursula ^b  

^a HELIOS KLINIKUM BERLIN BUCH   (Germany)

^b Arzneimittelkommission der deutschen Arzteschaft   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ELTROMBOPAG; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; GROWTH FACTOR; ROMIPLOSTIM; THROMBOPOIETIN; VASCULOTROPIN;

ADJUVANT THERAPY; ANTIANGIOGENIC ACTIVITY; BLOOD TRANSFUSION; BONE MARROW CELL; BONE MARROW TRANSPLANTATION; BREAST CANCER; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER SURGERY; CELL ACTIVATION; CELL DIFFERENTIATION; CELL FUNCTION; CELL MATURATION; CELL PROLIFERATION; CELL STIMULATION; CELL SURVIVAL; CHEMOTHERAPY; CHRONIC KIDNEY FAILURE; CONFERENCE PAPER; FEBRILE NEUTROPENIA; GENE EXPRESSION; HEAD AND NECK CANCER; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC CELL; HUMAN; HYPOPLASIA; IDIOPATHIC THROMBOCYTOPENIC PURPURA; MYELOID PROGENITOR CELL; NEUTROPHIL COUNT; ONCOLOGY; OVARY CANCER; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROPHYLAXIS; RADIOSENSITIVITY; SOLID TUMOR; THROMBOCYTOPENIA; THROMBOCYTOPENIC PURPURA; THROMBOCYTOPOIESIS; TRILINEAR HYPOPLASIA; UNSPECIFIED SIDE EFFECT; VENOUS THROMBOEMBOLISM;

CLINICAL TRIALS AS TOPIC; ERYTHROPOIETIN, RECOMBINANT; GRANULOCYTE COLONY STIMULATING FACTOR, RECOMBINANT; HEMATOPOIESIS; HUMANS; MEDICAL ONCOLOGY; NEOPLASMS; THROMBOPOIETIN;

EID: 77149156937     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2009.00514.x     Document Type: Conference Paper

References (34)

1. Shaheen M, Broxmeyer HE. The humoral regulation of hematopoiesis. In : Hoffman R, Benz EJ Jr., Shattil SJ, Furie B, Cohen HJ, Silberstein LE, McGlave P (eds). Hematology. Elsevier Churchill Livingstone, Philadelphia, PA, 2005 230 265.
2. Kaushansky K. Lineage-specific hematopoietic growth factors. N Engl J Med 2006 354 : 2034 2045.
3. Dingemanse J, Appel-Dingemanse S. Integrated pharmacokinetics and pharmacodynamics in drug development. Clin Pharmacokinet 2007 46 : 713 737.
4. Friberg LE, Henningsson A, Maas H, Nguyen L, Karlsson MO. Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. J Clin Oncol 2002 20 : 4713 4721.
5. Friberg LE, Karlsson MO. Mechanistic models for myelosuppression. Invest New Drugs 2003 21 : 183 194.
6. Kloft Ch, Wallin J, Henningsson A, Chatelut E, Karlsson MO. Population pharmacokinetic-pharmacodynamic model for neutropenia with patient subgroup identification: comparison across anticancer drugs. Clin Cancer Res 2006 12 : 5481 5490.
7. Slavin RG, Ferioli C, Tannenbaum SJ, Martin C, Blogg M, Lowe PJ. Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations. J Allergy Clin Immunol 2009 123 : 107 113.
8. Scholz M, Engel C, Loeffler M. Modelling human granulopoiesis under poly-chemotherapy with G-CSF support. J Math Biol 2005 50 : 397 439.
9. Veng-Pedersen P, Freise KJ, Schmidt RL, Widness JA. Pharmacokinetic differentiation of drug candidates using system analysis and physiological-based modelling. Comparison of C.E.R.A. and erythropoietin. J Pharm Pharmacol 2008 60 : 1321 1334.
10. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukaemia. Ann Intern Med 1966 64 : 328 340.
11. Calotta F, Re F, Polentarutti N, Sozzoni S, Mantovani A. Modulation of granulocyte survival and programmed cell death by cytokines and bacterial products. Blood 1992 80 : 2012 2020.
12. Nathan CF. Respiratory burst in adherent human neutrophils: triggering by colony-stimulating factors CSF-GM and CSF-G. Blood 1989 73 : 301 306.
13. Clark OAC, Lyman C, Castro AA, Clark LGO, Djulbegovic B. Colony stimulating factors for chemotherapy induced febrile neutropenia. Cochrane Database of Systematic Reviews 2000, Issue 4. Art. No.: CD003039. DOI :.
14. Cheng AC, Stephens DP, Currie BJ. Granulocyte-colony stimulating factor (G-CSF) as an adjunct to antibiotics in the treatment of pneumonia in adults. Cochrane Database of Systematic Reviews 2007, Issue 2. Art. No.: CD004400. DOI :.
15. Kuderer NM, Dale DC, Crawford J, Lyman GH. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 2007 25 : 3158 3167.
16. Aapro MS, Cameron DA, Pettengell R, Bohlius J, Crawford J, Ellis M et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 2006 42 : 2433 2453.
17. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Myeloid growth factors. http://www.nccn.org.
18. Lyman GH, Kuderer NM. Pegfilgrastim verbesserte Gesamtüberleben nicht selektierter Patienten. Onkologe 2008 14, Attachment.
19. Kaplinsky C, Trakhtenbrot L, Hardan I, Reichart M, Daniely M, Toren A et al. Tetraploid myeloid cells in donors of peripheral blood stem cells treated with rhG-CSF. Bone Marrow Transplant 2003 32 : 31 4.
20. Nagler A, Korenstein-Ilan A, Amiel A, Avivi L. Granulocyte colony-stimulating factor generates epigenetic and genetic alterations in lymphocytes of normal volunteer donors of stem cells. Exp Hematol 2004 32 : 122 130.
21. Amariglio N, Jacob-Hirsch J, Shimoni A, Leiba M, Rechavi G, Nagler A. Changes in gene expression pattern following granulocyte colony-stimulating factor administration to normal stem cell sibling donors. Acta Haematol 2007 117 : 68 73.
22. Fujii K, Ishimaru F, Kozuka T, Matsuo K, Nakase K, Kataoka I et al. Elevation of serum hepatocyte growth factor during granulocyte colony-stimulating factor-induced peripheral blood stem cell mobilization. Br J Haematol 2004 124 : 190 194.
23. McGuire TR, Kessinger A, Hock L, Sharp JG. Elevated transforming growth factor beta levels in the plasma of cytokine-treated cancer patients and normal allogeneic stem cell donors. Cytotherapy 2001 3 : 361 364.
24. Henke M, Laszig R, Rübe C, Schäfer U, Haase KD, Schilcher B et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003 362 : 1255 1260.
25. Leyland-Jones B, Semiglazov V, Pawlicki M, Pienkowski T, Tjulandin S, Manikhas G et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 2005 23 : 5960 5972.
26. Bennett CL, Silver SM, Djulbegovic B, Samaras AT, Blau CA, Gleason KJ et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008 299 : 914 924.
27. Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet 2009 373 : 1532 1542.
28. Li J, Yang C, Xia Y, Bertino A, Glaspy J, Roberts M et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 2001 98 : 3241 3248.
29. Basser RL, O'Flaherty E, Green M, Edmonds M, Nichol J, Menchaca DM et al. Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor. Blood 2002 99 : 2599 2602.
30. Bussel JB, Kuter DJ, George JN, McMillan R, Aledort LM, Conklin GT et al. AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N Engl J Med 2006 355 : 1672 1681.
31. Kuter DJ, Bussel JB, Lyons RM, Pullarkat V, Gernsheimer TB, Senecal FM et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet 2008 371 : 395 403.
32. Bussel JB, Cheng G, Saleh MN, Psaila B, Kovaleva L, Meddeb B et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 2007 357 : 2237 2247.
33. Bussel JB, Provan D, Shamsi T, Cheng G, Psaila B, Kovaleva L et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet 2009 373 : 641 648.
34. McHutchison JG, Dusheiko G, Shiffman ML, Rodriguez-Torres M, Sigal S, Bourliere M et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med 2007 357 : 2227 2236.